Ocular Therapeutix (OCUL) Announces Update from Centers for Medicare and Medicaid Services for Reimbursement of DEXTENZA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. QCOM
2. CBRS
3. FDX
4. USO
5. MU
6. SPY
7. KBH
8. HTZ
9. HON
10. JPM

Go back to Ocular Therapeutix (OCUL) Announces Update from Centers for Medicare and Medicaid Services for Reimbursement of DEXTENZA

Ocular Therapeutix (OCUL) Successfully Appeals Patent Case Against Mati Therapeutics, Inc

November 9, 2021 9:07 AM EST

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Court of Appeals for the Federal Circuit in Washington, D.C., invalidated a patent held by Mati Therapeutics, Inc. (Mati) relating to a drug delivery system containing dexamethasone. This decision affirms the judgment made in June 2020 by... More